Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Kuros Biosciences News

    7,50 CHF -0,53% -0,04 CHF
    In : 7,7293 € | 19.04.24 17:30:11 SIX Swiss Exchange aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2ALS5
    ISIN: CH0325814116
    US-Symbol: CSBTF
    Typ: Aktie

    Unternehmensmeldungen

    17.04.24 - DGAP
    Annual General Meeting of Kuros Biosciences approves all resolutions
    Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST
    08.03.24 - DGAP
    Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update
    Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST
    01.02.24 - DGAP
    Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference
    Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference 01.02.2024 / 07:00 CET/CEST
    31.01.24 - DGAP
    Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
    Kuros Biosciences AG / Key word(s): Regulatory Admission/Market Launch Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and ...
    04.01.24 - DGAP
    Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA
    Kuros Biosciences AG / Key word(s): Study results/Preliminary Results Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including ...
    28.11.23 - DGAP
    Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
    Kuros Biosciences AG / Key word(s): Regulatory Approval Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages 28.11.2023 / 18:00 CET/CEST
    13.07.23 - DGAP
    Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
    Kuros Biosciences AG / Key word(s): Study results Kuros Biosciences Announces Completion of Enrollment in the Fibrin-​PTH Phase 2 Trial 13.07.2023 / 19:29 CET/CEST
    21.02.23 - DGAP
    Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft 21.02.2023 / 07:00 ...
    23.11.22 - DGAP
    Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-​PTH 23.11.2022 / 07:00 CET/CEST
    02.11.22 - DGAP
    Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
    Kuros Biosciences AG / Key word(s): Study Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules 02.11.2022 / 07:00 CET/CEST
    19.10.22 - DGAP
    Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week 19.10.2022 / ...
    11.10.22 - DGAP
    Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST
    11.10.22 - DGAP
    Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
    Kuros Biosciences AG / Key word(s): Conference Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting 11.10.2022 / 07:00 CET/CEST
    23.08.22 - DGAP
    Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
    Kuros Biosciences AG / Key word(s): Corporate Action Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones 23.08.2022 / 07:00 CET/CEST
    31.05.22 - DGAP
    Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first ...
    18.05.22 - DGAP
    Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
    Kuros Biosciences AG / Key word(s): Product Launch Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S. 18.05.2022 / 07:00
    03.02.22 - DGAP
    Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications 03.02.2022 / 07:00
    20.01.22 - DGAP
    Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
    Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences publishes first-​in-human clinical data for Fibrin-​PTH (KUR-113) in treatment of open tibial shaft fractures ...
    28.09.21 - DGAP
    EQS-News: Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting
    EQS Group-​News: Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences to showcase new MagnetOs products at NASS 2021 Annual Meeting 28.09.2021 / 07:00
    09.09.21 - DGAP
    EQS-News: Kuros Biosciences Announces FDA 510(k) Clearance for MagnetOs Easypack PuttyHeadline
    EQS Group-​News: Kuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences Announces FDA 510(k) Clearance for MagnetOs Easypack PuttyHeadline 09.09.2021 / 07:00

    Newssuche

    Videos

    newspaper
    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »